Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Venetoclax plus obinutuzumab in CKT CLL: analysis from the CLL14 trial

Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, talks about venetoclax plus obinutuzumab in CKT CLL. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.